Pan Pharmaceutical has filed a request with the FDA to market a generic version of Axiron transdermal testosterone. Eli Lily is suing to block the request, claiming it violates seven of its patents.
Pharma plays games to block generic testosterone gels. They have been successful so far in paying off generic companies so that they withdraw their applications.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.